DexCom Aktie 2107726 / US2521311074
75.24
USD
0.35
USD
0.47%
20.11.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
DexCom Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2022 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2021 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2020 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2019 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2018 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2017 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2016 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2015 | DexCom Inc. | 0.00 | 0.00 | USD |
| 2014 | DexCom Inc. | 0.00 | 0.00 | USD |
Gewinn je Aktie- DexCom
| -0.1 17 | -0.4 18 | 0.3 19 | 1.3 20 | 0.4 21 | 0.8 22 | 1.3 23 |
Umsatz je Aktie- DexCom
| 2.1 17 | 2.9 18 | 4.0 19 | 4.9 20 | 6.1 21 | 6.8 22 | 8.5 23 |
KGV- DexCom
| 200 19 | 73.0 20 | 347 21 | 142 22 | 95.3 23 |
DexCom Inc.: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | -0.15 | -0.36 | 0.28 | 1.27 | 0.39 | 0.82 | 1.30 |
| Gewinn je Aktie unverwässert | -0.15 | -0.36 | 0.28 | 1.31 | 0.40 | 0.88 | 1.40 |
| Gewinn je Aktie verwässert | -0.15 | -0.36 | 0.27 | 1.27 | 0.39 | 0.80 | 1.30 |
| Dividende pro Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DexCom Inc.: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 2.08 | 2.92 | 4.00 | 4.94 | 6.12 | 6.81 | 8.51 |
| KGV (Jahresendkurs, EPS unverwässert) | - | - | 199.73 | 73.03 | 347.41 | 141.89 | 95.29 |
| KGV (Jahresendkurs, EPS verwässert) | - | - | 199.73 | 73.03 | 347.41 | 141.89 | 95.29 |
| KGV (Jahresendkurs) | - | - | 199.73 | 73.03 | 347.41 | 141.89 | 95.29 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 46.39 | 34.62 | 36.85 | 41.68 | 46.29 | 39.54 | 33.02 |
| Fremdkapitalquote in % | 53.61 | 65.38 | 63.15 | 58.32 | 53.71 | 60.46 | 66.98 |
DexCom Inc.: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 718.50 | 1’031.60 | 1’476.00 | 1’926.70 | 2’448.50 | 2’909.80 | 3’622.30 |
| Umsatzveränderung in % | 25.33 | 43.58 | 43.08 | 30.54 | 27.08 | 18.84 | 24.49 |
| Bruttoergebnis vom Umsatz | 492.10 | 663.90 | 931.50 | 1’280.10 | 1’680.50 | 1’875.60 | 2’280.80 |
| Bruttoergebnisveränderung in % | 30.05 | 34.91 | 40.31 | 37.42 | 31.28 | 11.61 | 21.60 |
| Operatives Ergebnis | -33.30 | -180.90 | 142.30 | 299.50 | 265.80 | 391.20 | 597.70 |
| Veränderung Operatives Ergebnis in % | 47.89 | -443.24 | - | 110.47 | -11.25 | 47.18 | 52.79 |
| Ergebnis vor Steuern | -48.60 | -126.50 | 104.20 | 225.00 | 173.90 | 390.80 | 710.40 |
| Veränderung Ergebnis vor Steuern in % | 25.12 | -160.29 | - | 115.93 | -22.71 | 124.73 | 81.78 |
| Ergebnis nach Steuer | -50.20 | -127.10 | 101.10 | 493.60 | 154.70 | 341.20 | 541.50 |
| Veränderung Ergebnis nach Steuer in % | 23.48 | -153.19 | - | 388.23 | -68.66 | 120.56 | 58.70 |
DexCom Inc.: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 485 | 1’253 | 1’512 | 2’556 | 2’612 | 3’260 | 4’196 |
| Langzeit Gesamtverbindlichk. pro Aktie | 0.99 | 2.86 | 3.14 | 5.05 | 4.86 | 3.68 | 6.85 |
| Eigenkapital | 419 | 663 | 883 | 1’827 | 2’252 | 2’132 | 2’069 |
| Veränderung Eigenkapital in % | 47.78 | 58.15 | 33.06 | 106.95 | 23.27 | -5.32 | -2.96 |
| Bilanzsumme | 904 | 1’916 | 2’395 | 4’383 | 4’864 | 5’392 | 6’265 |
| Veränderung Bilanzsumme in % | 124.45 | 111.92 | 25.00 | 82.99 | 10.97 | 10.86 | 16.19 |
DexCom Inc.: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | -0.15 | -0.36 | 0.28 | 1.31 | 0.40 | 0.88 | 1.40 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 25.64 | -148.48 | - | 371.23 | -69.41 | 119.10 | 60.10 |
| Gewinn je Aktie (verwässert) | -0.15 | -0.36 | 0.27 | 1.27 | 0.39 | 0.80 | 1.30 |
| Veränderung Gewinn je Aktie (verwässert) in % | 25.64 | -148.48 | - | 362.24 | -69.47 | 106.55 | 63.16 |
| Anzahl Mitarbeiter | 2’290 | 2’800 | 5’200 | 6’400 | 6’300 | 7’600 | 9’600 |
| Veränderung Anzahl Mitarbeiter in % | -0.43 | 22.27 | 85.71 | 23.08 | -1.56 | 20.63 | 26.32 |
DexCom Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| DexCom Inc. | Quartalszahlen | 06.02.2025 |
| DexCom Inc. | Quartalszahlen | 24.04.2025 |
| DexCom Inc. | Quartalszahlen | 24.07.2025 |
| DexCom Inc. | Quartalszahlen | 23.10.2025 |
DexCom Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 24.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 25.07.2024 |
| Hauptversammlung | Annual General Meeting | 22.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 25.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 08.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 26.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 27.07.2023 |
| Hauptversammlung | Annual General Meeting | 18.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 09.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 27.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 28.07.2022 |
| Hauptversammlung | Annual General Meeting | 19.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 28.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 10.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98.71 |
| Vanguard Group, Inc. (Subfiler) | 11.68 |
| The Vanguard Group, Inc. | 11.38 |
| Capital Research & Management Co. (Global Investors) | 4.60 |
| State Street Corp. | 4.27 |
| BlackRock Fund Advisors | 3.96 |
| Baillie Gifford & Co. | 3.84 |
| Vanguard Total Stock Market ETF | 3.26 |
| Vanguard 500 Index Fund | 2.69 |
| Sands Capital Management LLC | 2.64 |
| Geode Capital Management LLC | 2.54 |
| BlackRock Institutional Trust Co. NA | 2.23 |
| Vanguard Mid Cap Index Fund | 2.17 |
| Invesco QQQ Trust | 1.99 |
| Capital Research & Management Co. (World Investors) | 1.95 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 5’200 | 6’400 | 6’300 | 7’600 | 9’600 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.28 | 0.30 | 0.39 | 0.38 | 0.38 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1’969 | 3’425 | 3’684 | 3’669 | 4’426 |
| Summe Anlagevermögen | 426 | 958 | 1’179 | 1’723 | 1’839 |
| Summe Aktiva | 2’395 | 4’383 | 4’864 | 5’392 | 6’265 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 1’160 | 1’840 | 1’879 | 2’145 | 2’594 |
| Summe Fremdkapital | 1’512 | 2’556 | 2’612 | 3’260 | 4’196 |
| Summe Eigenkapital | 883 | 1’827 | 2’252 | 2’132 | 2’069 |
| Summe Passiva | 2’395 | 4’383 | 4’864 | 5’392 | 6’265 |
Adresse
| 6340 Sequence Drive, 92121 San Diego | |
| Telefon | +1 (858) 200-0200 |
| URL | http://www.dexcom.com |
Management
|
Barry J. Regan
Executive Vice President-Global Operations |
|
Bridgette P. Heller
Independent Director |
|
Donald M. Abbey
Executive VP-IT Quality & Regulatory Affairs |
|
Eric J. Topol
Independent Director |
|
Girish Naganathan
Chief Technology Officer & Executive VP |
|
Jacob S. Leach
Chief Operating Officer & Executive Vice President |
|
Jereme M Sylvain
Chief Financial Officer & Executive Vice President |
|
Karen M. Dahut
Independent Director |
|
Kevin Ronald Sayer
Chairman, President & Chief Executive Officer |
|
Kyle J. Malady
Independent Director |
|
Mark G. Foletta
Lead Independent Director |
|
Matt V. Dolan
Executive VP-Strategy & Corporate Development |
|
Michael Jon Brown
Chief Legal Officer & Executive Vice President |
|
Nicholas Augustinos
Independent Director |
|
Paul R. Flynn
Executive Vice President-Global Revenue |
|
Richard Alexander Collins
Independent Director |
|
Rimma Driscoll
Independent Director |
|
Sadie M Stern
Chief Human Resources Officer & Executive VP |
|
Sean Christensen
Vice President-Finance & Investor Relations |
|
Shelly R. Selvaraj
Chief Information Officer & Senior Vice President |
|
Steven R. Altman
Independent Director |
|
Steven Robert Pacelli
Executive VP & Managing Director-Dexcom Ventures |
|
Teri L. Lawver
Chief Commercial Officer & Executive VP |